Questions about Tamoxifen and the Future Use of Antiestrogens.

@article{Yao1998QuestionsAT,
  title={Questions about Tamoxifen and the Future Use of Antiestrogens.},
  author={Yao and Jordan},
  journal={The oncologist},
  year={1998},
  volume={3 2},
  pages={
          104-110
        }
}
  • Yao, Jordan
  • Published 1998
  • Medicine
  • The oncologist
Tamoxifen is the most widely prescribed anticancer drug in the world. It not only improves overall survival and decreases recurrence from breast cancer, but has beneficial effects on bone density and lipid profiles. Unfortunately, tamoxifen carries disadvantages such as unpleasant side effects and a questionable connection to endometrial carcinoma. However, after intense debate, the general consensus among the medical community is that the benefits of tamoxifen far outweigh the risks… Expand
Comparative Tolerability of First-Generation Selective Estrogen Receptor Modulators in Breast Cancer Treatment and Prevention
TLDR
Because of the weakness and scarcity of the data on toremifene, any conclusions about its tolerability remain tentative until outcomes of ongoing clinical trials in the adjuvant setting are known; the risk-to-benefit ratio for each agent should be carefully examined in determining the most advantageous regimen. Expand
Tamoxifen--what next?
TLDR
Establishing the comparative efficacies and optimal sequences that incorporate the newer endocrine agents will be central in determining the future role of hormonal therapy in ABC; the results of this work will determine the relative place of tamoxifen in what is a rapidly changing therapeutic environment. Expand
Preclinical and Clinical Experience with Fulvestrant (Faslodex) in Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer
TLDR
The efficacy of fulvestrant in sequential endocrine therapy and in combination with other agents appears promising and active investigations are ongoing to explore the clinical potential of this novel antiestrogen. Expand
Understanding the genotoxicity of tamoxifen?
TLDR
The current evidence for genotoxic mechanisms for tamoxifen carcinogenicity is reviewed, some inconsistencies in the data are discussed, and the mechanism of carcinogenic action is discussed. Expand
Endometrial and other primary cancers after tamoxifen treatment of breast cancer -- results of retrospective cohort study.
TLDR
The results support the IARC evaluation that tamoxifen is carcinogenic to humans and suggest that tamxifen does not increase the risk of other second primary cancers, however, therisk of individual second primary cancer cannot be reliably assessed due to a limited number of patients. Expand
Pomegranate extract demonstrate a selective estrogen receptor modulator profile in human tumor cell lines and in vivo models of estrogen deprivation.
TLDR
The findings suggest that PME displays a SERM profile and may have the potential for prevention of estrogen-dependent breast cancers with beneficial effects in other hormone-dependent tissues. Expand
Huaier aqueous extract suppresses human breast cancer cell proliferation through inhibition of estrogen receptor α signaling.
TLDR
Evidence is provided that Huaier extract is a novel estrogen receptor modulator and is a promising drug for the prevention and treatment of ERα-positive human breast cancers. Expand
Does tamoxifen enhance endothelial function by lowering the plasma levels of homocysteine?
TLDR
Tamoxifen reduces tHcy levels not only in patients with advanced breast cancer,2 but also in healthy women, indicating that its lowering effect is not only due to its antitumoral activity, but also to its direct effect on estrogen-regulated targets. Expand
Development of Hot Melt Extruded Solid Dispersion of Tamoxifen Citrate and Resveratrol for Synergistic Effects on Breast Cancer Cells
TLDR
HME-based simultaneous extrusion of TAM and RES formulation provides a suitable formulation strategy for breast cancer treatment and establishes proof of concept for extruding multiple drugs simultaneously for other applications in future. Expand
Pharmacological and Therapeutic Properties of Punica granatum Phytochemicals: Possible Roles in Breast Cancer
TLDR
Pomegranate extracts induced cell cycle arrest in the G0/G1 phase, and induced cytotoxicity in a dose- and time-dependent manner, and several polyphenols extracted from pomegranates inhibited the invasion potential, migration and viability of breast cancer cells. Expand
...
1
2
...

References

SHOWING 1-10 OF 58 REFERENCES
Should adjuvant tamoxifen therapy be stopped at 5 years?
TLDR
It is concluded that it will be difficult to demonstrate survival differences between 5 and 10 years of tamoxifen in clinical trials unless significant tamoxIFen-stimulated recurrences occur with continued therapy. Expand
A Realistic Clinical Perspective of Tamoxifen and Endometrial Carcinogenesis
TLDR
The goal of this review is to address concerns about tamoxifen’s potential carcinogenicity, re-evaluate the available data from laboratory biological models and those from clinical reports and put the whole issue into perspective. Expand
Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid.
TLDR
The combination of 9cRA and raloxifene, which has a high binding affinity for the estrogen receptor and a low level of estrogenic activity and does not promote growth of uterine epithelium, was evaluated for its chemopreventive activity in the well-accepted rat model of breast cancer induced by the carcinogen nitrosomethylurea. Expand
Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer.
TLDR
Positive evidence is provided that toremifene has antiatherogenic properties with potency to improve all lipoproteins that are associated with increased coronary heart disease (CHD) risk. Expand
Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer
TLDR
Preliminary evidence suggests that the agent is without effects on the liver or the hypothalamic-pituitary axis, and appears to be a promising new agent for treatment of advanced and early breast cancer. Expand
A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.
TLDR
Tamoxifen significantly reduced the rate of treatment failure at local and distant sites, tumors in the opposite breast, and the incidence of tumor recurrence after lumpectomy and breast irradiation and was attained with a low incidence of clinically appreciable toxic effects. Expand
Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.
TLDR
The outcome of patients in the B-14 trial through 10 years of follow-up indicated that tamoxifen therapy provided substantial benefit to patients with early stage disease, and questions arose about how long the observed benefit would persist. Expand
Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer.
TLDR
In postmenopausal women, treatment with tamoxifen is associated with preservation of the bone mineral density of the lumbar spine, and whether this favorable effect on bone mineraldensity is accompanied by a decrease in the risk of fractures remains to be determined. Expand
Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients.
TLDR
It is suggested that tamoxifen and toremifene produce comparable estrogenic effects in the uterus and vagina. Expand
Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study.
TLDR
The conclusion is that toremifene is an effective, safe and in clinical practice easily applied choice of treatment in estrogen receptor positive advanced breast cancer. Expand
...
1
2
3
4
5
...